Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC

Leeuwen, E. B. M. van; Cloosen, Silvie; Senden-Gijsbers, Birgit L. M. G.; Germeraad, Wilfred T.V.; Bos, Gerard M.J.

doi:10.1080/14653240500508166

Cited by 10 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[59][60][61] Plasmid DNA transfection can be efficient with newer methods 62 but in a head-to-head comparison, AdV vector was found to be superior. 63 In continuing investigations, we have also recently found broad and potent activation of multiple CD8 T-cell peptide specificities by AdV-engineered DCs 9 and broad T H 1 function of CD4 T cells activated by AdV/DCs compared with protein-loaded DCs. 29 In a previous trial in which GM-CSF/IL-4 DCs were transduced with both AdVMART1 and AdVgp100, 1 of 17 evaluable patients had a complete clinical response (ASH 2002, Haluska et al 64 ) and 3/12 patients with vitiligo were reported 65 More recently, a trial testing melanoma tumor RNA transfected, matured DC reported successful immunization of half of the subjects and superiority of ID immunization compared with intranodal delivery.…”

Section: Discussionmentioning

confidence: 99%

Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma

Butterfield¹,

Comin-Anduix²,

Vujanović³

et al. 2008

Journal of Immunotherapy

104

View full text Add to dashboard Cite

We performed a phase 1/2 trial testing the safety, toxicity, and immune response of a vaccine consisting of autologous dendritic cells (DCs) transduced with a replication-defective adenovirus (AdV) encoding the full-length melanoma antigen MART-1/Melan-A (MART-1). This vaccine was designed to activate MART-1-specific CD+8 and CD4+ T cells. Metastatic melanoma patients received 3 injections of 10(6) or 10(7) DCs, delivered intradermally. Cell surface phenotype and cytokine production of the DCs used for the vaccines were tested, and indicated intermediate maturity. CD8+ T-cell responses to MART-1 27-35 were assessed by both major histocompatibility complex class I tetramer and interferon (IFN)-gamma enzyme-linked immunosorbent spot (ELISPOT) before, during, and after each vaccine and CD4+ T-cell responses to MART-1 51-73 were followed by IFN-gamma ELISPOT. We also measured antigen response breadth. Determinant spreading from the immunizing antigen MART-1 to other melanoma antigens [gp100, tyrosinase, human melanoma antigen-A3 (MAGE-A3)] was assessed by IFN-gamma ELISPOT. Twenty-three patients were enrolled and 14 patients received all 3 scheduled DC vaccines. Significant CD8+ and/or CD4+ MART-1-specific T-cell responses were observed in 6/11 and 2/4 patients evaluated, respectively, indicating that the E1-deleted adenovirus encoding the cDNA for MART-1/Melan-A (AdVMART1)/DC vaccine activated both helper and killer T cells in vivo. Responses in CD8+ and CD4+ T cells to additional antigens were noted in 2 patients. The AdVMART1-transduced DC vaccine was safe and immunogenic in patients with metastatic melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma

Butterfield¹,

Comin-Anduix²,

Vujanović³

et al. 2008

Journal of Immunotherapy

104

View full text Add to dashboard Cite

show abstract

“…In regard to DC transduction efficiency, gene transfer and immune stimulation, viral transduction methods have been found to be superior to non-viral methods [10-12]. In addition to high gene transfer efficiency, transduction of DCs with adenovirus serotype 5 (Ad5)-based vectors offers many benefits over other viral vectors.…”

Section: Introductionmentioning

confidence: 99%

A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo

Thacker¹,

Nakayama²,

Smith

et al. 2009

Vaccine

View full text Add to dashboard Cite

Targeting viral vectors encoding tumor-associated antigens to dendritic cells (DCs) in vivo is likely to enhance the effectiveness of immunotherapeutic cancer vaccines. We have previously shown that genetic modification of adenovirus (Ad) 5 to incorporate CD40 ligand (CD40L) rather than native fiber allows selective transduction and activation of DCs in vitro. Here, we examine the capacity of Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access Author ManuscriptVaccine. Author manuscript; available in PMC 2010 November 23. Published in final edited form as:Vaccine.

show abstract

“…In one study, nucleofection and adenoviral transduction were compared in terms of their efficiency at transducing human MoDCs in vitro. The use of a fiber-modified adenoviral vector may therefore be preferable to nonviral gene delivery systems for DCs that will be used in cancer immunotherapy (72 (74). Therefore, electroporation of mRNA-encoding tumor antigens is a powerful technique to charge human DCs with tumor antigens and could provide tumor vaccines (75).…”

Section: Genetically Modified Dcsmentioning

confidence: 99%

The characterization and role of leukemia cell-derived dendritic cells in immunotherapy for leukemic diseases

Yuan

Song

Jiang

2012

Intractable Rare Dis Res

View full text Add to dashboard Cite

Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC

Cited by 10 publications

References 39 publications

Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma

Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma

A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo

The characterization and role of leukemia cell-derived dendritic cells in immunotherapy for leukemic diseases

Contact Info

Product

Resources

About